

- Insulin degludec/insulin aspart (IDegAsp) is a recently developed soluble co-formulation containing two insulin analogues.
- Basal (insulin degludec) and prandial (insulin aspart) components of IDegAsp do not interact and their distinct pharmacokinetic/pharmacodynamic profiles are not compromised by co-formulation.
- IDegAsp has been investigated extensively in the BOOST™ clinical trial programme, consisting of six randomised, controlled, treat-to-target trials with the inclusion of 2,413 subjects.
- The IDegAsp basal regime was non-inferior to the standard basal-bolus regime in type 1 diabetes, creating an innovative three dose regime which is convenient and less complex as compared to basal bolus regime.
- IDegAsp is a suitable, simpler option for intensification for patients with type 2 diabetes who fail to achieve good glycaemic control with basal insulin or premix insulin.

This summary slide represents the opinions of the authors. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).